Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

NCT00129753 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Terminated due to slow accrual.

Conditions

Hodgkin's Disease
Lymphoma

Interventions

DRUG: Alemtuzumab (Campath-1H)

Sponsor

M.D. Anderson Cancer Center